近日,全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。 GLP-1赛道的王座之争已无悬念,而专利悬崖、集采冲击与管线焦虑,正迫使跨国药企加速寻找下一个增长引擎。 GLP-1王座之争:礼来登顶 8月5日,礼来公布2026年上半年业绩——总营收427.73亿美元,同比增长49%。在目前已披露上半年业绩的头部跨国药企中,礼来的制药业务收入已位列...
Source Link近日,全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。 GLP-1赛道的王座之争已无悬念,而专利悬崖、集采冲击与管线焦虑,正迫使跨国药企加速寻找下一个增长引擎。 GLP-1王座之争:礼来登顶 8月5日,礼来公布2026年上半年业绩——总营收427.73亿美元,同比增长49%。在目前已披露上半年业绩的头部跨国药企中,礼来的制药业务收入已位列...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.